Lactate dehydrogenase A silencing in IDH mutant gliomas.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Neuro-Oncology

• Publication date

  2014-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/neuonc/not243PMID 24366912PMCID PMC3984548
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

  2013cited by this paper
• LDHA is necessary for the tumorigenicity of esophageal squamous cell carcinoma

  2013cited by this paper
• IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

  2012cited by this paper
• DNA hypermethylation and 1p Loss silence NHE‐1 in oligodendroglioma

  2012cited by this paper
• IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

  2012cited by this paper
• Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation

  2012cited by this paper
• Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma

  2012cited by this paper
• Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression

  2012cited by this paper
• Non-invasive assessment of IDH status in glioblastoma using dynamic 13 C MRS of hyperpolarized α-ketoglutarate

  2011cited by this paper
• 2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations

  2011cited by this paper
• Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

  2011cited by this paper
• Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA

  2011cited by this paper
• Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases.

  2011cited by this paper
• The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases

  2011cited by this paper
• Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.

  2011cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2010cited by this paper
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

  2010cited by this paper
• Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression

  2010cited by this paper
• IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

  2010cited by this paper
• 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2

  2010cited by this paper
• Oligodendroglioma cell lines containing t(1;19)(q10;p10).

  2010cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Faculty Opinions recommendation of Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.

  2009cited by this paper
• LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer

  2009cited by this paper
• Mutant metabolic enzymes are at the origin of gliomas.

  2009cited by this paper
• IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

  2009cited by this paper
• Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

  2009cited by this paper
• Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens

  2009cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Roles of p53, Myc and HIF-1 in Regulating Glycolysis — the Seventh Hallmark of Cancer

  2008cited by this paper
• Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer

  2006cited by this paper
• Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance.

  2006cited by this paper
• Lactate: mirror and motor of tumor malignancy.

  2004cited by this paper
• DNA methylation and gene silencing in cancer: which is the guilty party?

  2002cited by this paper
• Gene silencing in mammalian cells and the spread of DNA methylation

  2002cited by this paper
• Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.

  2001cited by this paper
• pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth.

  2001cited by this paper
• L-lactate dehydrogenase A4- and A3B isoforms are bona fide peroxisomal enzymes in rat liver. Evidence for involvement in intraperoxisomal NADH reoxidation.

  1996cited by this paper
• Hypoxic Regulation of Lactate Dehydrogenase A

  1995cited by this paper
• Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.

  1994cited by this paper
• Evolutionary relationship of a fish C type lactate dehydrogenase to other vertebrate lactate dehydrogenase isozymes

  1986cited by this paper
• LACTIC DEHYDROGENASE IN HUMAN NEOPLASTIC TISSUES.

  1964cited by this paper

• Integrative Analysis of Cytotoxic Lymphocytes‐Mediated Tumour Killing Related Genes Reveals LDHA as a Novel Glioblastoma Therapeutic Target

  2026cites this paper
• Quantitative susceptibility mapping for the comprehensive assessment of adult-type diffuse gliomas.

  2025cites this paper
• Differences in advanced radiologic features of glioma subtypes under the 2021 WHO classification of tumors of the central Nervous system.

  2025cites this paper
• Nano-Based Technology in Glioblastoma

  2025cites this paper
• Oxidative and Glycolytic Metabolism: Their Reciprocal Regulation and Dysregulation in Cancer

  2025cites this paper
• Mogroside V Restores Glycolytic Function via LDHA Promoter Demethylation Independent of Alternative Splicing in PCOS Granulosa Cells.

  2025cites this paper
• Nuclear-localized metabolic enzymes: emerging key players in tumor epigenetic regulation

  2025cites this paper
• The 1p/19q co-deletion induces targetable and imageable vulnerabilities in glucose metabolism in oligodendrogliomas

  2025cites this paper
• The Warburg hypothesis and the emergence of the mitochondrial metabolic theory of cancer

  2025cites this paper
• Mechanism analysis and targeted therapy of IDH gene mutation in glioma.

  2025cites this paper
• Therapeutic targeting of chromatin alterations in leukemia and solid tumors

  2025cites this paper
• D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells

  2024cites this paper
• Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma

  2024cites this paper
• IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications

  2024cites this paper
• A patient-derived cell model for malignant transformation in IDH-mutant glioma

  2024cites this paper
• Metabolic dysregulation of tricarboxylic acid cycle and oxidative phosphorylation in glioblastoma

  2024cites this paper
• A negative feedback loop underlies the Warburg effect

  2024cites this paper
• Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells

  2024cites this paper
• Amino Acid and Glucose Fermentation Maintain ATP Content in Mouse and Human Malignant Glioma Cells

  2024cites this paper
• GPR65 sensing tumor-derived lactate induces HMGB1 release from TAM via the cAMP/PKA/CREB pathway to promote glioma progression

  2024cites this paper
• Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity

  2024cites this paper
• U3 snoRNA‐mediated degradation of ZBTB7A regulates aerobic glycolysis in isocitrate dehydrogenase 1 wild‐type glioblastoma cells

  2023cites this paper
• Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer

  2023cites this paper
• Deuterium metabolic imaging for 3D mapping of glucose metabolism in humans with central nervous system lesions at 3T

  2023cites this paper
• The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability

  2023cites this paper
• On an Optimal Control Problem Describing Lactate Transport Inhibition

  2023cites this paper
• A bacterial enzyme may correct 2-HG accumulation in human cancers

  2023cites this paper
• A Preliminary Study Indicating Improvement in the Median Survival Time of Glioblastoma Multiforme Patients by the Application of Deuterium Depletion in Combination with Conventional Therapy

  2023cites this paper
• Dynamic modelling predicts lactate and IL-1β as interventional targets in metabolic-inflammation-clock regulatory loop in glioma.

  2023cites this paper
• A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma

  2023influential citation
• Mutant IDH in Gliomas: Role in Cancer and Treatment Options

  2023cites this paper
• Preclinical modeling of lower-grade gliomas

  2023cites this paper
• Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study

  2022cites this paper
• Revisiting the Warburg Effect with Focus on Lactate

  2022cites this paper
• LDHA: The Obstacle to T cell responses against tumor

  2022cites this paper
• Development of a novel glycolysis-related genes signature for isocitrate dehydrogenase 1-associated glioblastoma multiforme

  2022cites this paper
• Lactate dehydrogenases promote glioblastoma growth and invasion via a metabolic symbiosis

  2022cites this paper
• Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities

  2022cites this paper
• Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function

  2022cites this paper
• Different Approaches for the Profiling of Cancer Pathway-Related Genes in Glioblastoma Cells

  2022cites this paper
• An Epigenetic Role of Mitochondria in Cancer

  2022cites this paper
• Metabolic management of microenvironment acidity in glioblastoma

  2022cites this paper
• Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas

  2022cites this paper
• Metabolism-Associated DNA Methylation Signature Stratifies Lower-Grade Glioma Patients and Predicts Response to Immunotherapy

  2022cites this paper
• Genetic and Drug Inhibition of LDH-A: Effects on Murine Gliomas

  2022cites this paper
• LDH-A—Modulation and the Variability of LDH Isoenzyme Profiles in Murine Gliomas: A Link with Metabolic and Growth Responses

  2022cites this paper
• Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma.

  2022cites this paper
• Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma

  2022cites this paper
• Biology of IDH mutant cholangiocarcinoma

  2022cites this paper
• Deuterium magnetic resonance spectroscopy enables non-invasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas.

  2022cites this paper
• Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate.

  2022cites this paper
• Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis

  2021cites this paper
• The Roles of 2-Hydroxyglutarate

  2021cites this paper
• Glycolysis-associated lncRNAs identify a subgroup of cancer patients with poor prognoses and a high-infiltration immune microenvironment

  2021cites this paper
• Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations

  2021cites this paper
• Extracellular citrate and metabolic adaptations of cancer cells

  2021cites this paper
• Integration into cancer studies

  2021cites this paper
• Perfusion CT detects alterations in local cerebral flow of glioma related to IDH, MGMT and TERT status

  2021cites this paper
• Relationship of Carbohydrate Metabolism and Molecular Genetic Markers in Gliomas with Different Degree of Anaplasia

  2021cites this paper
• Accelerated Hyper-Versus Normofractionated Radiochemotherapy with Temozolomide in Patients with Glioblastoma: A Multicenter Retrospective Analysis.

  2021cites this paper
• “Aerobic glycolytic imaging” of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging

  2021cites this paper
• On an optimal control problem describing lactate production inhibition

  2021cites this paper
• HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells

  2021cites this paper
• Can the Mitochondrial Metabolic Theory Explain Better the Origin and Management of Cancer than Can the Somatic Mutation Theory?

  2021cites this paper
• Atomic Force Microscope Nanoindentation Analysis of Diffuse Astrocytic Tumor Elasticity: Relation with Tumor Histopathology

  2021cites this paper
• IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?

  2021cites this paper
• Speci c expression of lactate dehydrogenases in glioblastoma controls intercellular lactate transfer to promote tumor growth and invasion

  2021cites this paper
• Non-invasive assessment of telomere maintenance mechanisms in brain tumors

  2021cites this paper
• Novel Post-Translational Modifications and Molecular Substrates in Glioma Identified by Bioinformatics

  2021cites this paper
• The Acidic Brain—Glycolytic Switch in the Microenvironment of Malignant Glioma

  2021cites this paper
• Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report

  2021cites this paper
• IDH1R132H Mutation Inhibits the Proliferation and Glycolysis of Glioma Cells by Regulating the HIF-1α/LDHA Pathway

  2021cites this paper
• Altered Metabolism in Glioblastoma: Myeloid-Derived Suppressor Cell (MDSC) Fitness and Tumor-Infiltrating Lymphocyte (TIL) Dysfunction

  2021cites this paper
• Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma

  2020cites this paper
• Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential.

  2020cites this paper
• Development and application of analytical tools to study the origin, fate and impact of the oncometabolite 2-hydroxyglutarate and its lactone

  2020cites this paper
• Development of a Bioinformatics Framework for Identification and Validation of Genomic Biomarkers and Key Immunopathology Processes and Controllers in Infectious and Non-infectious Severe Inflammatory Response Syndrome

  2020cites this paper
• IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

  2020cites this paper
• How DNA methylation affects the Warburg effect

  2020cites this paper
• Lower Lactate Levels and Lower Intracellular pH in Patients with IDH-Mutant versus Wild-Type Gliomas

  2020cites this paper
• MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma

  2020cites this paper
• Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study

  2020cites this paper
• Sirtuin activation targets IDH-mutant tumors.

  2020cites this paper
• Polyunsaturated fatty acid-containing phosphatidic acids selectively interact with L-lactate dehydrogenase A and induce its secondary structural change and inactivation.

  2020cites this paper
• Emerging Roles and Therapeutic Interventions of Aerobic Glycolysis in Glioma

  2020cites this paper
• IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives

  2020cites this paper
• Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma

  2020cites this paper
• Generation of induced neural stem cells with inducible IDH1R132H for analysis of glioma development and drug testing

  2020cites this paper
• New Era of Diacylglycerol Kinase, Phosphatidic Acid and Phosphatidic Acid-Binding Protein

  2020cites this paper
• Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment

  2020cites this paper
• Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma

  2020cites this paper
• Role of Extracellular Vesicles in Glioma Progression: Deciphering cellular biological processes to clinical applications.

  2020cites this paper
• Magnetic resonance spectroscopy for the study of cns malignancies

  2020cites this paper
• Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.

  2020cites this paper
• Emerging Roles and Therapeutic Interventions of Aerobic Glycolysis in Glioma

  2020cites this paper
• Classification of glioma based on prognostic alternative splicing

  2019cites this paper
• Metabolic Reprogramming Associated with Aggressiveness Occurs in the G-CIMP-High Molecular Subtypes of IDH1mut Lower Grade Gliomas.

  2019cites this paper
• Friend or foe—IDH1 mutations in glioma 10 years on

  2019cites this paper
• The Implication of Anti-angiogenic Treatment of Malignancies on Human Metabolism

  2019cites this paper
• C-13 Hyperpolarized MR Spectroscopy for Metabolic Imaging of Brain Tumors

  2019cites this paper